EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
…, EF Mysler, JAP Da Silva, G Poór… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative …
…, C Duftner, HS Jensen, P Duhaut, G Poór… - Arthritis & …, 2012 - Wiley Online Library
The objective of this study was to develop European League Against Rheumatism/American
College of Rheumatology classification criteria for polymyalgia rheumatica (PMR). …
College of Rheumatology classification criteria for polymyalgia rheumatica (PMR). …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
…, E Mysler, P Nash, K Pavelka, G Poór… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international Task …
Against Rheumatism (EULAR) RA management recommendations. A large international Task …
Epidemiology of Paget's disease in Europe: the prevalence is decreasing
G Poór, J Donáth, B Fornet… - Journal of bone and …, 2006 - academic.oup.com
This study estimated changes in the age‐ and sex‐specific prevalence of Paget's disease of
bone in six European towns over a 20‐year period. Declines in prevalence were observed …
bone in six European towns over a 20‐year period. Declines in prevalence were observed …
Relapsing polychondritis
P Gergely Jr, G Poór - Best Practice & Research Clinical Rheumatology, 2004 - Elsevier
… Anemia and renal involvement are poor prognostic factors at all ages. In patients younger
than 51 years of age factors predicting decreased survival include saddle nose deformity, …
than 51 years of age factors predicting decreased survival include saddle nose deformity, …
Interim report and recommendations of the World Health Organization task-force for osteoporosis
The World Health Organization has established a task force charged with the mission of
developing a worldwide strategy for osteoporosis management and prevention. A direct …
developing a worldwide strategy for osteoporosis management and prevention. A direct …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
…, Z Li, IB McInnes, EF Mysler, P Nash, G Poor… - Annals of the …, 2023 - ard.bmj.com
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An international …
recommendations addressing the most recent developments in the field. Methods An international …
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with …
…, A Rebrov, T Balazs, R Cseuz, E Drescher, G Poor - The Lancet, 2018 - thelancet.com
Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended
for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when …
for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when …
Determinants of reduced survival following hip fractures in men.
G Poór, EJ Atkinson, WM O'Fallon… - … and Related Research …, 1995 - journals.lww.com
To assess determinants of poor survival after hip fractures in men, a population-based cohort
study was conducted among 131 men in Rochester, MN, who had their first hip fracture …
study was conducted among 131 men in Rochester, MN, who had their first hip fracture …
Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis
L Bucsi, G Poór - Osteoarthritis and Cartilage, 1998 - Elsevier
Patients with osteoarthritis (OA) of the knee were treated with chondroitin sulfate (CS,
Condrosulf R , IBSA, Lugano, CH) in a randomized, double-blind, placebo-controlled study, …
Condrosulf R , IBSA, Lugano, CH) in a randomized, double-blind, placebo-controlled study, …